New obesity drug CRB-913 enters human testing
NCT ID NCT07310901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called CRB-913 for weight loss in people with obesity. It involves 252 participants and has two parts: first, measuring how the drug works in healthy adults, then comparing three doses against a placebo over 12 weeks. The goal is to check safety and how the drug affects body weight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CRB-913
What this could lead to
If successful, this could lead to a new weight-loss medication for people with obesity.
What could go wrong
This is an early Phase 1b trial, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESE BUT OTHERWISE HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research Sites
DeLand, Florida, 32720, United States
-
Alliance Clinical
Las Vegas, Nevada, 89109, United States
-
Arizona Clinical Trials
Chandler, Arizona, 85225, United States
-
Central Alabama Research
Birmingham, Alabama, 35209, United States
-
Flourish Research
San Antonio, Texas, 78229, United States
-
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky, 40213, United States
-
Lucas Research
Morehead City, North Carolina, 28557, United States
-
Medpace Clinical Pharmacology
Cincinnati, Ohio, 45227, United States
-
Neurobehavioral Research
Cedarhurst, New York, 11516, United States
-
Prospective Research Innovations
Rancho Cucamonga, California, 91730, United States
-
Quotient Sciences
Miami, Florida, 33126, United States
-
Rochester Clinical Research
Rochester, New York, 14609, United States
-
Tampa Bay Medical Research
Largo, Florida, 33761, United States
-
Velocity Clinical Research
Cleveland, Ohio, 44122, United States
-
Velocity Clinical Research
Dallas, Texas, 75230, United States